Denosumab has also been approved for the treatment of bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer, for the treatment of bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer, and for the treatment of osteoporosis due to decreased bone turnover in patients with multiple myeloma and bone metastases from breast cancer [177]. The gene discussed is CYP19A1; the disease is breast carcinoma.